Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuyang Jiedu Granules Combined With ART for Immune Reconstitution Failure in HIV
NCT07698548Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Randomised trial of Fuyang Jiedu Granules in human immunodeficiency virus infection (HIV) and immune reconstitution inflammatory syndrome (IRIS) (2 arms), sponsored by Beijing University of Chinese Medicine. Primary endpoints: Absolute CD4+ T-cell count at 48 weeks and Immune reconstitution response rate at 48 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Fuyang Jiedu Granules
03
Conditions
human immunodeficiency virus infection (HIV)immune reconstitution inflammatory syndrome (IRIS)
Beyond the preview
Go deeper on NCT07698548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698548.